Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Noninvasive biomarkers in monitoring kidney allograft health

O’Callaghan, John M.; Knight, Simon R.

Current Opinion in Organ Transplantation: August 2019 - Volume 24 - Issue 4 - p 411–415
doi: 10.1097/MOT.0000000000000658
KIDNEY PANCREAS: Edited by Matthew Cooper
Buy

Purpose of review A key aspect of posttransplant management is to identify and treat graft injury before it becomes irreversible. The gold-standard for detection is histology, but biopsy is uncomfortable for the patient and carries a risk of complications. Detection of changes at a molecular level may preempt histological injury, and thereby identify injury earlier.

Recent findings Indicators of immune system activation, such as candidate chemokines CXCL9 and CXCL10, and by-products of neutrophil activity, have been related to acute rejection and early allograft function. Transcriptomic studies of multiple-gene panels have identified candidate combinations that have proven very promising in risk-stratification and prediction of acute rejection, as well as diagnosis of both T-cell-mediated and antibody-mediated rejection. Serum and urine cell-free DNA is also a promising area of investigation, particularly in antibody-mediated rejection.

Summary Noninvasive, rapid, and accurate tests for risk-prediction and diagnosis in renal transplant allografts are urgently required. The ideal candidate is one that can be measured in either urine or blood, is cheap, and is both sensitive and specific for the condition of interest. Numerous strategies have been proposed, with varying degrees of clinical and preclinical success. A few that meet the essential criteria have been evaluated; a few have made it as far as clinical testing.

Nuffield Department of Surgical Sciences, Centre for Evidence in Transplantation, University of Oxford, Oxford, UK

Correspondence to John M. O’Callaghan, MBBS, BSc, DPhil, FRCS, Oxford Transplant Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Old Road, Oxford OX3 7LE, UK. Tel: +44 0186 522 7131; e-mail: john.ocallaghan@ouh.nhs.uk

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.